Table 1.

Patient characteristics in each study

Author (yrs.)	N	Age (mean yrs.)	HG (Grade, N)	Treatment	TP53	Method	IHC antibody	IHC cutoff	PCR Exons	Death in 2 yrs. n (%)
Papai (1997) [10]	21	20	17 (Grade IIb)	NC + surgery	expression	IHC	DO-7	5%		8 (38)
			4 (Grade IIa)
Goto (1998) [11]	32	16	23 (Grade III)	NC + surgery	expression	IHC/PCR	DO-7/Rsp53	> 0%	MS	14 (44)
			9 (Grade IV)
Jensen (1998) [12]	25	67	9 (Grade III)	surgery	expression	IHC	DO-7	10%		11 (44)
			16 (Grade IV)
Yokoyama (1998) [13]	17	15	8 (Grade III)	NC + surgery	mutation	PCR*			4-8	1 (6)
			7 (Grade IV)
Gorlick (1999) [14]	53	17	11 (Grade I)	NC + surgery	expression	IHC	1801/DO-7	> 0%		16 (30)
			24 (Grade II)
			10 (Grade III)
			8 (Grade IV)
Tsuchiya (2000) [16]	27	15	NA	NC + surgery	mutation	PCR*			5-9	11 (41)
Uozaki (2000) [17]	70	16	43 (Grade III)	NC + surgery	expression	IHC	DO-7	10%		17 (24)
			27 (Grade IV)
Oda (2000) [15]	25	17	6 (Grade III)	NC + surgery	expression	IHC	NR	10%		4 (16)
			19 (Grade IV)
Kawaguchi (2002) [18]	23	55	8 (Grade III)	surgery	mutation	IHC/PCR	1801	10%	5-9	12 (52)
			15 (Grade IV)
Tsai (2004) [21]	22	16	3 (Grade II)	NC + surgery	expression	IHC	DO-7	5%		9 (41)
			11 (Grade IIa)
			8 (Grade III)
Ferrari (2004) [20]	19	15	NA	surgery	expression	IHC	DO-7	25%		3 (16)
Kaseta (2008) [22]	35	30	4 (Low grade)	NC + surgery	expression	IHC	DO-7	25%		NA
			31 (High grade)
Ozger (2009) [23]	45	20	NA	NC + surgery	expression	IHC	DO-7	10%		6 (13)
Boulytcheva (2010) [24]	40	NA	4 (Grade I)	surgery	expression	IHC	DO-7	10%		NA
			22 (Grade II)
			2 (Grade III)
			12 (Grade IV)
Hu (2010) [25]	44	25	5 (Grade I)	NC + surgery	expression	IHC	NR	10%		NA
			16 (Grade II)
			16 (Grade III)
			7 (Grade IV)
Seidinger (2011) [26]	41	NA	NA	surgery	mutation	IHC/PCR	DO-7	NR	10	12 (29)
Wu (2012) [27]	56	Range (13-37)	56 (Grade IIb)	NC + surgery	expression	IHC	DO-7	10%		NA

Note: HG, histological grades; N, number; NC, neoadjuvant chemotherapy;

^*PCR/single-strand conformational polymorphism.